Overview

Key figures*

 

 

 

 

 

 

kEUR

H1 2021

H1 2020

Change

 

 

Revenue

135,136

87,808

53.9%

 

 

Custom Projects

76,207

33,504

127.5%

 

 

Contract Manufacturing

45,765

42,901

6.7%

 

 

Generics & Cosmetics

13,164

11,403

15.4%

 

 

EBITDA

39,889

18,519

115.4%

 

 

Adjusted 1 EBITDA

43,240

18,519

133.5%

 

 

Adjusted 1 EBITDA in % of revenue

32.0%

21.1%

10.9 ppts

 

 

Operating result (EBIT)

30,803

10,160

203.2%

 

 

Operating result (EBIT) in % of revenue

22.8%

11.6%

11.2 ppts

 

 

Result for the period

24,623

7,831

214.4%

 

 

Result for the period in % of revenue

18.2%

8.9%

9.3 ppts

 

 

Earnings per share (EUR), basic

0.79

0.26

203.6%

 

 

Return on net operating assets (RONOA)

25.6%

12.2%

13.4 ppts

 

 

Cash and cash equivalents (end of period)

187,362

8,727

 

 

Net cash flow from operating activities

41,038

13,949

194.2%

 

 

Capital expenditures

24,989

9,465

164.0%

 

 

Capital expenditures in % of revenue

18.5%

10.8%

7.7 ppts

 

 

Total assets (end of period)

571,950

313,888

82.2%

 

 

Equity ratio (end of period)

67.4%

50.0%

17.4 ppts

 

 

Employees (# of FTEs, average)

1,026

896

14.5%

 

 

* This table and report include references to operational indicators, such as customer projects and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.

1 Adjusted EBITDA excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic.